3155F Cytogen test marrow b/4 treatment
Also known as: baseline flow cytometry documented, pre-treatment flow cytometry
Performance measure documenting baseline flow cytometry testing performed prior to initiation of cancer treatment or therapy, used for hematologic malignancy assessment and treatment planning.
In Plain Language
blood test to check cancer cells before treatment
Clinical Context
Quality metric tracking appropriate baseline testing in patients with suspected or diagnosed hematologic malignancies (leukemia, lymphoma) before chemotherapy or immunotherapy initiation.
RVU Information
CPT 3155F does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Documentation should include the clinical indication, service details, and any applicable performance metrics. Coverage may vary by payer — verify acceptance before billing.
Specialties
Frequently Asked Questions
What is CPT code 3155F?
CPT 3155F (Cytogen test marrow b/4 treatment) is a Other code. Performance measure documenting baseline flow cytometry testing performed prior to initiation of cancer treatment or therapy, used for hematologic malignancy assessment and treatment planning.
Who uses CPT code 3155F?
CPT 3155F is used by Oncology, Hematology, Pathology. Quality metric tracking appropriate baseline testing in patients with suspected or diagnosed hematologic malignancies (leukemia, lymphoma) before chemotherapy or immunotherapy initiation.
When is CPT 3155F used?
Quality metric tracking appropriate baseline testing in patients with suspected or diagnosed hematologic malignancies (leukemia, lymphoma) before chemotherapy or immunotherapy initiation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.